195 related articles for article (PubMed ID: 17250601)
1. Usefulness of ploidy, AgNOR and immunocytochemistry for differentiating benign and malignant cells in serous effusions.
Palaoro LA; Blanco AM; Gamboni M; Rocher AE; Rotenberg RG
Cytopathology; 2007 Feb; 18(1):33-9. PubMed ID: 17250601
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of AgNOR technique in the interpretation of serous effusions].
Rocher AE; Blanco AM; Palaoro LA
Rev Med Chil; 2000 Sep; 128(9):963-8. PubMed ID: 11349500
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].
Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP
Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046
[TBL] [Abstract][Full Text] [Related]
6. [Significance of FCM-DNA ploidy pattern, AgNOR counting, hTERT and PCNA expression in differentiating malignant from benign serous effusion].
Wu LY; Liu BR; Lu J; Ling MD; Chen J; Li P; Jiang Y
Ai Zheng; 2007 Feb; 26(2):178-82. PubMed ID: 17298749
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
8. Argyrophilic nucleolar organizer regions in benign and malignant mesothelial lesions.
Vacharadze K; Burkadze G; Turashvili G; Kiria N
Georgian Med News; 2005 Nov; (128):91-3. PubMed ID: 16369075
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
Ueda J; Iwata T; Ono M; Takahashi M
Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
[TBL] [Abstract][Full Text] [Related]
10. Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions.
Mohanty SK; Dey P; Rana P
Anal Quant Cytol Histol; 2003 Oct; 25(5):273-6. PubMed ID: 14603724
[TBL] [Abstract][Full Text] [Related]
11. Patterns of argyrophilic nucleolar organiser regions in pleural and peritoneal effusions.
Khan SA; Chaudhry NA; Khalid AW; Akhtar GN; Ibne-Rasa SN
J Coll Physicians Surg Pak; 2006 Jun; 16(6):412-5. PubMed ID: 16787619
[TBL] [Abstract][Full Text] [Related]
12. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
Marsan C; Gaulier A; Sabatier P; Garcia R
Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
[TBL] [Abstract][Full Text] [Related]
13. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.
Carrillo R; Sneige N; el-Naggar AK
Acta Cytol; 1994; 38(3):367-72. PubMed ID: 8191825
[TBL] [Abstract][Full Text] [Related]
14. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
15. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
Joseph MG; Banerjee D; Harris P; Gibson S; McFadden RG
Mod Pathol; 1995 Aug; 8(6):686-93. PubMed ID: 8532707
[TBL] [Abstract][Full Text] [Related]
16. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions.
Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M
Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433
[TBL] [Abstract][Full Text] [Related]
17. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
18. Silver-stained nucleolar organizer regions in normal and dysplastic cervical lesions: correlation with DNA ploidy and S-phase fraction by flow cytometry.
Singh M; Prasad S; Kalra N; Singh U; Shukla Y
Oncology; 2006; 71(5-6):411-6. PubMed ID: 17785995
[TBL] [Abstract][Full Text] [Related]
19. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
20. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
